Search
for
Sort by
Research 121–150 of 1000+
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- TGF-β Signaling: a Potential Therapeutic Target of Single Herbs and Extracts for Renal Fibrosis
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- 700 Oncostatin M is upstream of JAK-STAT signaling during the murine hair cycle
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- JAK inhibitors in dermatology: The promise of a new drug class
- Janus Kinase inhibitors in dermatology: a review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles